Imaging tumors with a special radiodrug targeting HER2 protein
A Study to Evaluate 68Ga-Her2-affibody PET/CT Imaging of Her2 Expression in Tumors
NA · Peking University First Hospital · NCT06289517
This study is testing a new imaging drug that targets the HER2 protein to see if it can help doctors better identify and understand different cancers, especially breast cancer.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking University First Hospital (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT06289517 on ClinicalTrials.gov |
What this trial studies
This project investigates the use of 68Ga-Her2-affibody, a radiodrug targeting the HER2 protein, to assess its diagnostic efficacy and safety in identifying HER2 expression in various cancers. The study aims to provide a novel imaging method that can enhance the determination of HER2 status in breast cancer and offer valuable insights for early diagnosis, accurate staging, and treatment decisions in other malignant tumors like lung, gastrointestinal, and bladder cancers. By utilizing PET imaging, the study seeks to gather comprehensive information that traditional biopsy methods may miss.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed or suspected cancer who are willing to provide informed consent.
Not a fit: Patients without cancer or those who do not express HER2 may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more accurate diagnoses and better treatment strategies for patients with HER2-positive cancers.
How similar studies have performed: Other studies have shown promise in using targeted imaging agents for cancer diagnostics, indicating potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: \- patients with confirmed or suspected cancer; Signed written informed consent Exclusion Criteria: \-
Where this trial is running
Beijing, Beijing Municipality
- Peking University First Hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Study coordinator: Lei Yin, Dr
- Email: jack-yin@163.com
- Phone: +8610835725252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neoplasms, 68Ga-Her2-affibody, PET/CT